Insider Buying: Standard BioTools (NASDAQ:LAB) Director Acquires 150,000 Shares of Stock

Standard BioTools Inc. (NASDAQ:LAB) Director Casdin Partners Master Fund, L acquired 150,000 shares of the firm’s stock in a transaction on Thursday, December 4th. The shares were bought at an average cost of $1.45 per share, for a total transaction of $217,500.00. Following the completion of the acquisition, the director directly owned 72,100,000 shares of the company’s stock, valued at approximately $104,545,000. This represents a 0.21% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Casdin Partners Master Fund, L also recently made the following trade(s):

• On Tuesday, December 2nd, Casdin Partners Master Fund, L bought 125,000 shares of Standard BioTools stock. The stock was bought at an average cost of $1.42 per share, with a total value of $177,500.00.
• On Wednesday, December 3rd, Casdin Partners Master Fund, L purchased 75,000 shares of Standard BioTools stock. The stock was bought at an average cost of $1.44 per share, for a total transaction of $108,000.00.
• On Tuesday, November 25th, Casdin Partners Master Fund, L purchased 7,550,000 shares of Standard BioTools stock. The stock was bought at an average price of $1.30 per share, for a total transaction of $9,815,000.00.
• On Monday, November 24th, Casdin Partners Master Fund, L acquired 150,000 shares of Standard BioTools stock. The shares were bought at an average cost of $1.43 per share, with a total value of $214,500.00.
• On Thursday, November 20th, Casdin Partners Master Fund, L bought 450,000 shares of Standard BioTools stock. The stock was purchased at an average price of $1.30 per share, for a total transaction of $585,000.00.
• On Wednesday, November 19th, Casdin Partners Master Fund, L bought 350,000 shares of Standard BioTools stock. The stock was purchased at an average cost of $1.28 per share, for a total transaction of $448,000.00.
• On Tuesday, November 18th, Casdin Partners Master Fund, L bought 275,000 shares of Standard BioTools stock. The shares were purchased at an average price of $1.23 per share, with a total value of $338,250.00.
• On Monday, November 17th, Casdin Partners Master Fund, L purchased 225,000 shares of Standard BioTools stock. The shares were purchased at an average cost of $1.22 per share, with a total value of $274,500.00.
• On Friday, November 14th, Casdin Partners Master Fund, L purchased 250,000 shares of Standard BioTools stock. The stock was purchased at an average price of $1.24 per share, for a total transaction of $310,000.00.
• On Thursday, November 13th, Casdin Partners Master Fund, L acquired 450,000 shares of Standard BioTools stock. The shares were purchased at an average cost of $1.20 per share, for a total transaction of $540,000.00.

Standard BioTools Stock Performance

Shares of NASDAQ LAB remained flat at $1.44 during mid-day trading on Thursday. 1,185,059 shares of the stock traded hands, compared to its average volume of 2,075,536. Standard BioTools Inc. has a 12 month low of $0.92 and a 12 month high of $2.25. The firm’s fifty day moving average price is $1.30 and its two-hundred day moving average price is $1.26.

Hedge Funds Weigh In On Standard BioTools

Several large investors have recently made changes to their positions in LAB. Mak Capital One LLC boosted its holdings in Standard BioTools by 184.6% in the third quarter. Mak Capital One LLC now owns 15,931,806 shares of the company’s stock valued at $20,711,000 after acquiring an additional 10,334,384 shares during the last quarter. Long Focus Capital Management LLC acquired a new position in Standard BioTools during the 1st quarter valued at about $7,236,000. Casdin Capital LLC boosted its stake in shares of Standard BioTools by 1.9% in the 3rd quarter. Casdin Capital LLC now owns 77,558,856 shares of the company’s stock valued at $100,827,000 after purchasing an additional 1,483,220 shares during the last quarter. Kent Lake PR LLC bought a new position in shares of Standard BioTools in the 2nd quarter valued at about $1,200,000. Finally, Nuveen LLC acquired a new stake in shares of Standard BioTools during the 1st quarter worth approximately $862,000. Institutional investors and hedge funds own 53.74% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on LAB shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Standard BioTools in a research report on Wednesday, October 8th. Cowen lowered Standard BioTools from a “buy” rating to a “hold” rating in a research note on Wednesday, August 13th. Wall Street Zen downgraded shares of Standard BioTools from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 8th. Finally, TD Cowen decreased their price objective on shares of Standard BioTools from $1.55 to $1.35 and set a “hold” rating on the stock in a report on Wednesday, November 5th. Three research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Standard BioTools has a consensus rating of “Reduce” and an average price target of $1.35.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.